{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:45:10Z","timestamp":1786981510984,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Background<\/jats:italic>\n                    The recommended dose of rasburicase is quite expensive, thus limiting its use. Whether a lower dose of rasburicase would be equally effective for critically ill children, who often have more complicated situations and a higher risk of hospital death, is still unknown.\n                    <jats:italic>Objective<\/jats:italic>\n                    To explore the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies who are at high risk of tumour lysis syndrome.\n                    <jats:italic>Setting<\/jats:italic>\n                    A single-centre retrospective cohort study.\n                    <jats:italic>Method<\/jats:italic>\n                    Children with haematological malignancies who had a history of rasburicase exposure during an intensive care unit stay were enrolled. Patients were divided into two groups according to the initial dosage of rasburicase: the standard-dose group (&gt;\u00a00.1\u00a0mg\/kg\/day) and the low-dose group (\u2264\u00a00.1\u00a0mg\/kg\/day). The adverse events and short-term prognosis of the two groups were compared.\n                    <jats:italic>Results<\/jats:italic>\n                    Thirty-seven children were selected, 22 in the standard-dose group and 15 in the low-dose group. The most common tumour type was Burkitt\u2019s lymphoma (81%), followed by acute lymphoblastic leukaemia (11%). All patients were at high risk of tumour lysis syndrome, and 73% of them had 3 or more tumour lysis syndrome risk factors. The uric acid levels of 90% of patients with hyperuricaemia returned to the normal range within 12\u00a0h (100% in the standard-dose group and 75% in the low-dose group,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00.083). Eighty-four percent of patients presented serious complications, including tumour lysis syndrome (73%), acute kidney injury (59%), renal replacement treatment (24%), respiratory failure (24%), disseminated intravascular coagulation (16%) and heart failure (11%). There was no significant difference in the incidence of serious complications between the two groups. The overall 7-day and 28-day survival rates after intensive care unit admission were 86% and 84%, respectively. The average length of stay in the intensive care unit was 9.92\u00a0\u00b1\u00a05.13\u00a0days. Neither the short-term mortality nor the length of stay in the intensive care unit were significantly different between the two groups.\n                    <jats:italic>Conclusion<\/jats:italic>\n                    Low-dose rasburicase is effective and may be an acceptable choice for critically ill children with haematological malignancies.\n                  <\/jats:p>","DOI":"10.1007\/s11096-020-01144-8","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T12:02:37Z","timestamp":1600948957000},"page":"1440-1446","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5000-8014","authenticated-orcid":false,"given":"Yuxin","family":"Pei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujian","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqiong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"issue":"1","key":"1144_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","volume":"127","author":"MS Cairo","year":"2004","unstructured":"Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3\u201311. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05094.x.","journal-title":"Br J Haematol"},{"issue":"5","key":"1144_CR2","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/hon.2668","volume":"37","author":"B Rahmani","year":"2019","unstructured":"Rahmani B, Patel S, Seyam O, Gandhi J, Reid I, Smith N, et al. Current understanding of tumor lysis syndrome. Hematol Oncol. 2019;37(5):537\u201347. https:\/\/doi.org\/10.1002\/hon.2668.","journal-title":"Hematol Oncol"},{"issue":"3","key":"1144_CR3","doi-asserted-by":"publisher","first-page":"CD006945","DOI":"10.1002\/14651858.cd006945.pub4","volume":"3","author":"DK Cheuk","year":"2017","unstructured":"Cheuk DK, Chiang AK, Chan GC, Ha SY. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cochrane Database Syst Rev. 2017;3(3):CD006945. https:\/\/doi.org\/10.1002\/14651858.cd006945.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1144_CR4","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","volume":"149","author":"MS Cairo","year":"2010","unstructured":"Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149(4):578\u201386. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08143.x.","journal-title":"Br J Haematol"},{"issue":"8","key":"1144_CR5","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1080\/13696998.2019.1603155","volume":"22","author":"S Hu","year":"2019","unstructured":"Hu S, Han Y, Zhang W, Zhang T, Yao X, Liu L. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China. J Med Econ. 2019;22(8):742\u201350. https:\/\/doi.org\/10.1080\/13696998.2019.1603155.","journal-title":"J Med Econ."},{"issue":"10","key":"1144_CR6","doi-asserted-by":"publisher","first-page":"e27236","DOI":"10.1002\/pbc.27236","volume":"65","author":"DA Savva","year":"2018","unstructured":"Savva DA, Herrera N, Rohatgi R. Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population. Pediatr Blood Cancer. 2018;65(10):e27236. https:\/\/doi.org\/10.1002\/pbc.27236.","journal-title":"Pediatr Blood Cancer"},{"key":"1144_CR7","doi-asserted-by":"publisher","unstructured":"Sun XF, Zhen ZJ, Xia Y, Lin SX, Zhu J, Wang J et al. [Outcome of children and adolescents with Burkitt lymphoma and diffuse large B cell lymphoma treated with a modified NHL-BFM-90 protocol]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2013;34(12):1032-7. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2013.12.008.","DOI":"10.3760\/cma.j.issn.0253-2727.2013.12.008"},{"issue":"4","key":"1144_CR8","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1046\/j.1365-2141.2003.04134.x","volume":"120","author":"MS Cairo","year":"2003","unstructured":"Cairo MS, Sposto R, Perkins SL, Meadows AT, Hoover-Regan ML, Anderson JR, et al. Burkitt\u2019s and Burkitt-like lymphoma in children and adolescents: a review of the Children\u2019s Cancer Group experience. Br J Haematol. 2003;120(4):660\u201370. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04134.x.","journal-title":"Br J Haematol"},{"issue":"4","key":"1144_CR9","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s12288-018-0938-9","volume":"34","author":"A Philips","year":"2018","unstructured":"Philips A, Radhakrishnan V, Ganesan P, Ganesan TS, Ramamurthy J, Dhanushkodi M, et al. Efficacy of Single Dose Rasburicase (1.5\u00a0mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome. Indian J Hematol Blood Transf. 2018;34(4):618\u201322. https:\/\/doi.org\/10.1007\/s12288-018-0938-9.","journal-title":"Indian J Hematol Blood Transf"},{"issue":"5","key":"1144_CR10","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/bjh.14689","volume":"181","author":"E Syrimi","year":"2018","unstructured":"Syrimi E, Gunasekera S, Norton A, Velangi M, Motwani J, Hiwarkar P. Single dose Rasburicase is a clinically effective pharmacoeconomic approach for preventing tumour lysis syndrome in children with high tumour burden. Br J Haematol. 2018;181(5):696\u20138. https:\/\/doi.org\/10.1111\/bjh.14689.","journal-title":"Br J Haematol"},{"issue":"5","key":"1144_CR11","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/bjh.13403","volume":"169","author":"GL Jones","year":"2015","unstructured":"Jones GL, Will A, Jackson GH, Webb NJ, Rule S. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2015;169(5):661\u201371. https:\/\/doi.org\/10.1111\/bjh.13403.","journal-title":"Br J Haematol"},{"issue":"4","key":"1144_CR12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/bjh.12415","volume":"162","author":"M Darmon","year":"2013","unstructured":"Darmon M, Vincent F, Camous L, Canet E, Bonmati C, Braun T, et al. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en R\u00e9animation Respiratoire et Onco-H\u00e9matologique. Br J Haematol. 2013;162(4):489\u201397. https:\/\/doi.org\/10.1111\/bjh.12415.","journal-title":"Br J Haematol"},{"issue":"1","key":"1144_CR13","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/cc11454","volume":"17","author":"JA Kellum","year":"2013","unstructured":"Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Critical Care (London, England). 2013;17(1):204. https:\/\/doi.org\/10.1186\/cc11454.","journal-title":"Critical Care (London, England)."},{"issue":"2","key":"1144_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3969\/j.issn.1673-5323.2011.02.005","volume":"16","author":"JP Fang","year":"2011","unstructured":"Fang JP, Luo XQ, Tu LM, Lai DB, Sun XF, Chen JL, et al. A multiple-center clinical study on the therapy for childhood acute lymphoblastic leukemia by using GZ-2002 ALL protocol. J China Pediat Blood Cancer. 2011;16(2):18\u201323. https:\/\/doi.org\/10.3969\/j.issn.1673-5323.2011.02.005.","journal-title":"J China Pediat Blood Cancer"},{"issue":"4","key":"1144_CR15","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.15159","volume":"184","author":"R Citrin","year":"2019","unstructured":"Citrin R, Getz KD, Li Y, Huang YS, Horowitz JP, Seif AE, et al. The epidemiology of rasburicase use in paediatric patients with acute lymphoblastic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 2019;184(4):684\u20138. https:\/\/doi.org\/10.1111\/bjh.15159.","journal-title":"Br J Haematol"},{"issue":"12","key":"1144_CR16","doi-asserted-by":"publisher","first-page":"e27401","DOI":"10.1002\/pbc.27401","volume":"65","author":"KG Gopakumar","year":"2018","unstructured":"Gopakumar KG, Seetharam S, Km JK, Nair M, Rajeswari B, Cs G, et al. Risk-based management strategy and outcomes of tumor lysis syndrome in children with leukemia\/lymphoma: analysis from a resource-limited setting. Pediatr Blood Cancer. 2018;65(12):e27401. https:\/\/doi.org\/10.1002\/pbc.27401.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"1144_CR17","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1093\/annonc\/mdr490","volume":"23","author":"S Vadhan-Raj","year":"2012","unstructured":"Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, et al. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012;23(6):1640\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdr490.","journal-title":"Ann Oncol"},{"issue":"6","key":"1144_CR18","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1592\/phco.26.6.806","volume":"26","author":"AM McDonnell","year":"2006","unstructured":"McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall PD. Single-dose rasburicase 6\u00a0mg in the management of tumor lysis syndrome in adults. Pharmacotherapy. 2006;26(6):806\u201312. https:\/\/doi.org\/10.1592\/phco.26.6.806.","journal-title":"Pharmacotherapy."},{"key":"1144_CR19","doi-asserted-by":"publisher","unstructured":"Gopakumar KG, Thankamony P, Seetharam S, P K. Treatment of tumor lysis syndrome in children with leukemia\/lymphoma in resource-limited settings: Efficacy of a fixed low-dose rasburicase. Pediatric Hematol Oncol. 2017;34(4):206\u201311. https:\/\/doi.org\/10.1080\/08880018.2017.1348415.","DOI":"10.1080\/08880018.2017.1348415"},{"issue":"10","key":"1144_CR20","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s00277-014-2141-x","volume":"93","author":"P Wohlfarth","year":"2014","unstructured":"Wohlfarth P, Staudinger T, Sperr WR, Bojic A, Robak O, Hermann A, et al. Prognostic factors, long-term survival, and outcome of cancer patients receiving chemotherapy in the intensive care unit. Ann Hematol. 2014;93(10):1629\u201336. https:\/\/doi.org\/10.1007\/s00277-014-2141-x.","journal-title":"Ann Hematol"},{"issue":"1","key":"1144_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/annonc\/mdh029","volume":"15","author":"H van den Berg","year":"2004","unstructured":"van den Berg H, Reintsema AM. Renal tubular damage in rasburicase: risks of alkalinisation. Ann Oncol. 2004;15(1):175\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdh029.","journal-title":"Ann Oncol"},{"issue":"4","key":"1144_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/jcpt.12061","volume":"38","author":"X Feng","year":"2013","unstructured":"Feng X, Dong K, Pham D, Pence S, Inciardi J, Bhutada NS. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis. J Clin Pharm Ther. 2013;38(4):301\u20138. https:\/\/doi.org\/10.1111\/jcpt.12061.","journal-title":"J Clin Pharm Ther"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01144-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-020-01144-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01144-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T01:04:30Z","timestamp":1632445470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-020-01144-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1144"],"URL":"https:\/\/doi.org\/10.1007\/s11096-020-01144-8","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,24]]},"assertion":[{"value":"14 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have declared no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Medical Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University approved this study [No.2020-092].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}